Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Leukemia

  Free Subscription


12.03.2018

3 Am J Hematol
5 Ann Hematol
1 Blood
2 BMC Cancer
2 Bone Marrow Transplant
14 Br J Haematol
3 Cancer
2 Clin Infect Dis
1 Exp Cell Res
1 Exp Hematol
3 Int J Hematol
2 J Clin Oncol
2 J Natl Cancer Inst
1 Leuk Lymphoma
3 Leuk Res
1 Leukemia
1 Oncogene
2 Oncol Rep


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Hematol

  1. ELLIOTT MA, Tefferi A
    Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
    Am J Hematol. 2018;93:578-587.
    PubMed     Text format     Abstract available

  2. OGDEN J, Yui J, Ali W, Mudireddy M, et al
    Pre-Anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia.
    Am J Hematol. 2018 Mar 6. doi: 10.1002/ajh.25083.
    PubMed     Text format    

  3. CANAANI J, Labopin M, Huang XJ, Arcese W, et al
    T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia. A report from the Acute Leukemia Working Party of the EBMT.
    Am J Hematol. 2018 Mar 2. doi: 10.1002/ajh.25082.
    PubMed     Text format     Abstract available


    Ann Hematol

  4. PARK S, Choi H, Kim HJ, Ahn JS, et al
    Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.
    Ann Hematol. 2018 Mar 2. pii: 10.1007/s00277-018-3260.
    PubMed     Text format     Abstract available

  5. HA J, Kim B, Hahn S, Lee ST, et al
    A patient with B-cell acute lymphoblastic leukemia with PAX5-ETV6 rearrangement with dic(9;12)(p13;p13) identified by chromosomal microarray.
    Ann Hematol. 2018 Mar 8. pii: 10.1007/s00277-018-3291.
    PubMed     Text format    

  6. SCAPPATICCI GB, Marini BL, Nachar VR, Uebel JR, et al
    Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Ann Hematol. 2018;97:573-584.
    PubMed     Text format     Abstract available

  7. HARADA K, Doki N, Miyazaki Y, Wakita A, et al
    Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.
    Ann Hematol. 2018 Mar 1. pii: 10.1007/s00277-018-3281.
    PubMed     Text format    

  8. LO WJ, Lin CL, Chang YC, Bai LY, et al
    Total body irradiation tremendously impair the proliferation, differentiation and chromosomal integrity of bone marrow-derived mesenchymal stromal stem cells.
    Ann Hematol. 2018;97:697-707.
    PubMed     Text format     Abstract available


    Blood

  9. SHOMALI W, Gotlib J
    Myelophthisic marrow involved by breast cancer and acute myeloid leukemia.
    Blood. 2018;131:1036.
    PubMed     Text format    


    BMC Cancer

  10. TAHIR SK, Smith ML, Hessler P, Rapp LR, et al
    Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    BMC Cancer. 2017;17:399.
    PubMed     Text format     Abstract available

  11. MENU E, Beaufils N, Usseglio F, Balducci E, et al
    First case of B ALL with KMT2A-MAML2 rearrangement: a case report.
    BMC Cancer. 2017;17:363.
    PubMed     Text format     Abstract available


    Bone Marrow Transplant

  12. CHENG Z, Zhou L, Hu K, Dai Y, et al
    Prognostic significance of microRNA-99a in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Bone Marrow Transplant. 2018 Mar 7. pii: 10.1038/s41409-018-0146.
    PubMed     Text format     Abstract available

  13. VAN DE PEPPEL RJ, von dem Borne PA, le Cessie S, de Boer MGJ, et al
    A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS.
    Bone Marrow Transplant. 2017;52:883-888.
    PubMed     Text format     Abstract available


    Br J Haematol

  14. TSUKAMOTO S, Kumazoe M, Huang Y, Lesnick C, et al
    SphK1 inhibitor potentiates the anti-cancer effect of EGCG on leukaemia cells.
    Br J Haematol. 2017;178:155-158.
    PubMed     Text format    

  15. TUCKER DL, Mihailescu L, Riordan R, Rule S, et al
    Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
    Br J Haematol. 2016 May 12. doi: 10.1111/bjh.14118.
    PubMed     Text format    

  16. NIBLOCK A, McConville DO, Morrison PJ
    Zygodactyly is strongly associated with Acute Myeloid Leukaemia.
    Br J Haematol. 2017;177:659-660.
    PubMed     Text format    

  17. EYRE TA, Fox CP, Shankara P, Went R, et al
    Idelalisib-Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia.
    Br J Haematol. 2017;177:486-491.
    PubMed     Text format    

  18. FLEMING S, Ong DM, Jackson K, Avery S, et al
    Partial response after induction chemotherapy has clinical relevance in acute myeloid leukaemia.
    Br J Haematol. 2017;177:328-330.
    PubMed     Text format    

  19. DELGADO J, Bielig T, Bonet L, Carnero-Montoro E, et al
    Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens.
    Br J Haematol. 2017;177:147-150.
    PubMed     Text format    

  20. TRACY I, Tapper W, Parker A, Gardiner A, et al
    Type C TP53-CDKN1A pathway dysfunction occurs independently of CDKN1A gene polymorphisms in chronic lymphocytic leukaemia and is associated with TP53 abnormalities.
    Br J Haematol. 2017;178:824-826.
    PubMed     Text format    

  21. ABID MB, De Mel S
    Does ponatinib cross the blood-brain barrier?
    Br J Haematol. 2017;179:497-498.
    PubMed     Text format    

  22. TAN RMR, Ganau M, Jeelani NUO, Tahir Z, et al
    Central nervous system aspergillosis resembling haemorrhagic brain infarct in a paediatric leukaemia patient.
    Br J Haematol. 2017;178:642-645.
    PubMed     Text format    

  23. SCHEFFOLD A, Jebaraj BMC, Jaramillo S, Tausch E, et al
    Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial.
    Br J Haematol. 2017;179:342-346.
    PubMed     Text format    

  24. GORDON MJ, Raess PW, Young K, Spurgeon SEF, et al
    Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
    Br J Haematol. 2017;179:501-503.
    PubMed     Text format    

  25. MUSGRAVE KM, van Delft FW, Avery PJ, Clack RM, et al
    Cerebral sinovenous thrombosis in children and young adults with acute lymphoblastic leukaemia - a cohort study from the United Kingdom.
    Br J Haematol. 2017;179:667-669.
    PubMed     Text format    

  26. VAN DER HELM LH, Berger G, Diepstra A, Huls G, et al
    Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.
    Br J Haematol. 2017;178:810-812.
    PubMed     Text format    

  27. RAU RE, Carroll AJ, Heerema NA, Arland L, et al
    Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia.
    Br J Haematol. 2017;179:843-846.
    PubMed     Text format    


    Cancer

  28. EFFICACE F, Castagnetti F, Martino B, Breccia M, et al
    Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31323.
    PubMed     Text format     Abstract available

  29. KANTARJIAN HM, Su Y, Jabbour EJ, Bhattacharyya H, et al
    Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31317.
    PubMed     Text format     Abstract available

  30. XUAN L, Wang Y, Huang F, Jiang E, et al
    Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31295.
    PubMed     Text format     Abstract available


    Clin Infect Dis

  31. HAKIM H, Dallas R, Wolf J, Tang L, et al
    Gut Microbiome Composition Predicts Infection Risk during Chemotherapy in Children with Acute Lymphoblastic Leukemia.
    Clin Infect Dis. 2018 Mar 6. pii: 4922398. doi: 10.1093.
    PubMed     Text format     Abstract available

  32. HAKIM H, Dallas R, Wolf J, Tang L, et al
    Gut Microbiome Composition Predicts Infection Risk during Chemotherapy in Children with Acute Lymphoblastic Leukemia.
    Clin Infect Dis. 2018 Mar 3. pii: 4919579. doi: 10.1093.
    PubMed     Text format     Abstract available


    Exp Cell Res

  33. TIAN WL, Guo R, Wang F, Jiang ZX, et al
    The IRF9-SIRT1-P53 Axis is Involved in the Growth of Human Acute Myeloid Leukemia.
    Exp Cell Res. 2018 Feb 28. pii: S0014-4827(18)30120.
    PubMed     Text format     Abstract available


    Exp Hematol

  34. CHOI EJ, Kim MS, Yoo NJ, Lee SH, et al
    Mutational analysis of hypermutation-related POLE gene in acute leukemias and lymphomas.
    Exp Hematol. 2017;48:39-40.
    PubMed     Text format    


    Int J Hematol

  35. DELIA D, Mizutani S
    The DNA damage response pathway in normal hematopoiesis and malignancies.
    Int J Hematol. 2017;106:328-334.
    PubMed     Text format     Abstract available

  36. MIYOSHI H, Ohshima K
    Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan.
    Int J Hematol. 2018 Mar 3. pii: 10.1007/s12185-018-2430.
    PubMed     Text format     Abstract available

  37. SANO H, Mochizuki K, Kobayashi S, Ohara Y, et al
    T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia.
    Int J Hematol. 2018 Mar 5. pii: 10.1007/s12185-018-2423.
    PubMed     Text format     Abstract available


    J Clin Oncol

  38. GORE L, Kearns PR, de Martino Lee ML, De Souza CA, et al
    Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
    J Clin Oncol. 2018 Mar 2:JCO2017759597. doi: 10.1200/JCO.2017.75.9597.
    PubMed     Text format     Abstract available

  39. STANULLA M, Dagdan E, Zaliova M, Moricke A, et al
    IKZF1(plus) Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2018 Mar 2:JCO2017743617. doi: 10.1200/JCO.2017.74.3617.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  40. BILLIET T, Elens I, Sleurs C, Uyttebroeck A, et al
    Brain Connectivity and Cognitive Flexibility in Nonirradiated Adult Survivors of Childhood Leukemia.
    J Natl Cancer Inst. 2018 Mar 5. pii: 4921181. doi: 10.1093.
    PubMed     Text format     Abstract available

  41. WANG M, Lindberg J, Klevebring D, Nilsson C, et al
    Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.
    J Natl Cancer Inst. 2018 Mar 1. pii: 4916692. doi: 10.1093.
    PubMed     Text format     Abstract available


    Leuk Lymphoma

  42. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Text format     Abstract available


    Leuk Res

  43. GANZEL C, Rouvio O, Avivi I, Magen H, et al
    Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
    Leuk Res. 2018;68:9-14.
    PubMed     Text format     Abstract available

  44. SAILLARD C, Elkaim E, Rey J, d'Incan E, et al
    Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients.
    Leuk Res. 2018;68:29-31.
    PubMed     Text format    

  45. HIWASE D, Tan P, D'Rozario J, Taper J, et al
    Efficacy and safety of nilotinib 300mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Leuk Res. 2018;67:109-115.
    PubMed     Text format     Abstract available


    Leukemia

  46. PETROV JC, Wada M, Pinz KG, Yan LE, et al
    Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
    Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0075.
    PubMed     Text format     Abstract available


    Oncogene

  47. ZHU Y, Lu L, Qiao C, Shan Y, et al
    Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
    Oncogene. 2018 Mar 7. pii: 10.1038/s41388-018-0157.
    PubMed     Text format     Abstract available


    Oncol Rep

  48. KONG X, Luo J, Xu T, Zhou Y, et al
    Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP.
    Oncol Rep. 2017;37:3423-3432.
    PubMed     Text format     Abstract available

  49. KIM DM, Jang H, Shin MG, Kim JH, et al
    beta-catenin induces expression of prohibitin gene in acute leukemic cells.
    Oncol Rep. 2017;37:3201-3208.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: